AstraZeneca India gets Enhertu nod for first-line HER2 breast cancer
CDSCO approval expands the blockbuster drug's label to the most common HER2-positive cancer setting in India.
— 3 earlier stories on Astrazeneca Pharma India Ltd. →What's new
- CDSCO approved Enhertu for first-line treatment of HER2-positive metastatic breast cancer in combination with pertuzumab.
- The indication targets roughly 20-25% of India's breast cancer patients, the most common cancer in Indian women.
- Enhertu is a global blockbuster with over $3 billion in annual sales worldwide.
Why this matters
This is a label expansion in a high-prevalence cancer subtype, creating a direct new revenue stream for AstraZeneca India. The company's revenue grew 33% in FY26 on oncology launches; this approval widens the addressable market for its highest-profile drug. The combination with pertuzumab positions Enhertu in the frontline setting, which typically carries longer treatment durations and higher volumes than later-line options.
What we're watching
- Pricing and reimbursement decisions for the new indication in India.
- Speed of commercial launch and impact on quarterly sales trajectory.
- Whether the frontline approval triggers further label expansions in India.
The full read
AstraZeneca Pharma India just landed its biggest label expansion yet. CDSCO approved Enhertu for first-line HER2-positive metastatic breast cancer, the setting where the largest number of Indian patients are treated. That subgroup, roughly 20-25% of all breast cancer cases in the country, is now eligible for a drug with over $3 billion in annual global sales. The approval pairs Enhertu with pertuzumab and places it squarely in frontline therapy, where treatment durations are longer and volumes are higher than later-line settings. For AstraZeneca India, which posted 33% revenue growth in FY26 on oncology launches, this widens the addressable market for its most important product. The open question is pricing. Enhertu commands premium prices globally; the domestic launch economics will determine how much of the global blockbuster translates into Indian revenue. A mid-cap pharmaceutical company with a ₹20,646 cr market cap now has a frontline oncology asset in the country's most common cancer.
Questions answered
- What exact patient group does the new Enhertu approval cover?
- Adults with unresectable or metastatic HER2-positive breast cancer receiving first-line treatment. The drug is approved in combination with pertuzumab, a standard HER2-targeted antibody.
- How does this change Enhertu's commercial potential in India?
- It moves Enhertu into the frontline treatment setting, where patients are typically treated for longer periods than in later-line settings. The HER2-positive subtype accounts for roughly 20-25% of India's breast cancer cases, making this the largest addressable population for the drug yet.
- What is Enhertu's global scale?
- Enhertu generated over $3 billion in global sales in the last financial year, making it one of AstraZeneca's most important oncology assets worldwide.
- How does this fit into AstraZeneca India's recent growth?
- The company's revenue grew 33% in FY26, driven by oncology drug launches. This approval adds another high-value product to that growth engine, though India pricing and adoption timelines will determine the domestic revenue impact.
Astrazeneca Pharma India Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ASTRAZEN →- 11 Jun 2026 · 10:38 AM IST AstraZeneca India gets Enhertu nod for first-line HER2 breast cancer
- 16d ago AstraZeneca Pharma India revenue climbs 33% on oncology drug launches
- 16d ago AstraZeneca Pharma India profit rises to ₹1.9 billion
- 21d ago AstraZeneca India wins CDSCO nod for Calquence in MCL